Veru Inc.

VERU

US92536C1036

Personal Products

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
1.42 ^USD	+7.58%		+6.77%	+97.22%

May. 14	B. Riley Securities Starts Very With Buy Rating, $5 Price Target	MT
May. 08	Earnings Flash (VERU) VERU Posts Q2 Revenue $4.1M	MT

Veru Inc. Provides Revenue Guidance for the Rest of Fiscal Year 2020

August 13, 2020 at 08:00 am EDT

Veru Inc. provided revenue guidance for the rest of fiscal year 2020. Looking forward to the rest of fiscal year 2020, the company expects the company's revenues to continue to be strong and growing towards a record year.

Latest news about Veru Inc.

B. Riley Securities Starts Very With Buy Rating, $5 Price Target	May. 14	MT
Earnings Flash (VERU) VERU Posts Q2 Revenue $4.1M	May. 08	MT
Transcript : Veru Inc., Q2 2024 Earnings Call, May 08, 2024	May. 08
HC Wainwright Adjusts Veru Price Target to $3 From $2, Maintains Buy Rating	May. 06	MT
Veru Inc. Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss	Apr. 30	CI
Oppenheimer Cuts Veru Price Target to $5 From $7, Maintains Outperform Rating	Apr. 15	MT
Veru Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Apr. 01	CI
Raymond James Starts Very With Outperform Rating, $3 Price Target	Mar. 28	MT
Certain Options of Veru Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	Mar. 12	CI
Certain Common Stock of Veru Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	Mar. 12	CI
Veru Inc. Appoints Louis Aronne as Chief Medical Advisor and A Member of the Scientific Advisory Board	Mar. 12	CI
Veru Inc. Announces New Scientific Advisory Board for Its Enobosarm Program for High Quality Weight Loss	Feb. 20	CI
Transcript : Veru Inc., Q1 2024 Earnings Call, Feb 08, 2024	Feb. 08
Veru Inc. Announces U.S. Food and Drug Administration Clearance of Investigational New Drug Application for its Phase 2b Clinical Study	Feb. 06	CI
Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with Glp-1 Drugs for Weight Loss	Jan. 08	CI
Transcript : Veru Inc. - Special Call	Jan. 04
Veru Prices $33 Million Offering; Shares Fall	Dec. 14	MT
Veru Launching Public Offering of Shares	Dec. 13	MT
Veru Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	Dec. 08	CI
North American Morning Briefing : Stock Futures, -2-	Dec. 04	DJ
Veru Inc. Reports Muscle Data from 5 Clinical Studies of Enobosarm	23-10-04	CI
Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication	23-09-26	CI
Veru Inc. Announces Clinical Data from Its Discontinued Phase 3 ARTEST Clinical Trial of Enobosarm Monotherapy	23-09-11	CI
Oppenheimer Adjusts Veru Price Target to $7 From $9, Maintains Outperform Rating	23-08-14	MT
Transcript : Veru Inc., Q3 2023 Earnings Call, Aug 10, 2023	23-08-10

Chart Veru Inc.

Duration

Period

More charts

Company Profile

Veru Inc. is a biopharmaceutical company. The Company is focused on developing medicines for the for the treatment of hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and other viral-related ARDS and for the management of breast and prostate cancers. The Company offers two FDA approved products within its sexual health program, including ENTADFI (tadalafil 5mg and finasteride 5mg capsule), for the treatment of benign prostatic hyperplasia and FC2 Female Condom (internal condom) (FC2), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. Its breast cancer drug pipeline has four clinical development programs for two drugs, such as enobosarm, an oral selective androgen receptor targeting agonist, and sabizabulin, an oral cytoskeleton disruptor. Its prostate cancer drug pipeline includes sabizabulin, VERU-100 and zuclomiphene citrate.

Sector

Personal Products

Calendar

2024-06-18 - Annual General Meeting

More about the company